MAT Waivered Prescriber Support Initiative Presents: New Data on Fentanyl

Friday, February 19, 2021, 12:00 AM - Wednesday, August 31, 2022, 12:00 AM, Online

As U.S. fentanyl deaths increased 10-fold from 2013 to 2018, this toll was concentrated in the Midwest, Appalachia, and New England. Unfortunately, fentanyl has now spread to the Western U.S. According to a recent study, in which investigators systematically collected publicly available medical examiner/coroner data from 2019 and 2020, across all jurisdictions with available data - including Arizona, California, Seattle, Denver, Houston, Dallas-Fort Worth - fentanyl deaths increased. Additionally, available data from 2020 shows further growth. During this time, the share of the national synthetic narcotic mortality in Western states nearly tripled. Co-involvement of fentanyl with other substances has also increased. Based on current trajectories, fentanyl deaths in these Western jurisdictions are about 3-4 years behind the Eastern and Midwestern U.S. We therefore have time - and many tools - to avert another public health disaster. This presentation will review a recently published paper that evaluated fentanyl use in the Western US and will present new tools and strategies available to address the rise in fentanyl use and prevent further deaths.

Release Date: February 19, 2021
Expiration Date: September 29, 2022
Estimated Time to Complete: 1 hour
Registration Fee: FREE

Recorded on December 8, 2020

AMA PRA Category 1 Credits™ (1.00 hours), Non-Physician Participation Credit (1.00 hours)

1. Distinguish three (3) data points indicating the rise in fentanyl deaths between Eastern and Western states.
2. Identify two (2) substances co-involved with fentanyl deaths in western US, particularly in Los Angeles, Phoenix, Houston.
3. Develop strategies and public health approaches to proactively prevent fentanyl deaths.

In support of improving patient care, Stanford Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Credit Designation

American Medical Association (AMA)
Stanford Medicine designates this Enduring Material for a maximum of 1.00 AMA PRA Category 1 Credits^TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Bibliography
Provider Resources: http://www.uclaisap.org/ca-hubandspoke/html/provider-resources.html
Factsheets and Toolkits: http://uclaisap.org/MATPrescriberSupport/html/factsheets-toolkits.html

Accessibility Statement
 Stanford University School of Medicine is committed to ensuring that its programs, services, goods and facilities are accessible to individuals with disabilities as specified under Section 504 of the Rehabilitation Act of 1973 and the Americans with Disabilities Amendments Act of 2008.  If you have needs that require special accommodations, including dietary concerns, please contact the CME Conference Coordinator.

Cultural and Linguistic Competency
The planners and speakers of this CME activity have been encouraged to address cultural issues relevant to their topic area for the purpose of complying with California Assembly Bill 1195. Moreover, the Stanford University School of Medicine Multicultural Health Portal contains many useful cultural and linguistic competency tools including culture guides, language access information and pertinent state and federal laws.  You are encouraged to visit the Multicultural Health Portal: http://lane.stanford.edu/portals/cultural.html

For CME general questions, please contact 
     Ph: (650)-497-8554
     Email: [email protected]

The Stanford University School of Medicine adheres to ACCME Criteria, Standards and Policies regarding industry support of continuing medical education.

There are no relevant financial relationships with ACCME-defined commercial interests for anyone who was in control of the content of this activity.